ADVFN Logo
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Mind Medicine Mindmed Inc

Mind Medicine Mindmed Inc (MMED)

14.90
0.00
( 0.00% )
Updated: 20:00:00

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
14.90
Bid
14.90
Ask
14.90
Volume
-
0.00 Day's Range 0.00
3.30 52 Week Range 16.40
Previous Close
14.90
Open
-
Last Trade
Last Trade Time
-
Average Volume (3m)
-
Financial Volume
-
VWAP
-

MMED Latest News

No news to show yet.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000CS
40000000CS
120000000CS
2610.2217.0212765964.716.44.77642311.50929357CS
528.25124.0601503766.6516.43.3393628.87768875CS
15610.82265.1960784314.0816.80.622481162.46222158CS
26010.81264.3031784844.0916.80.623198132.95429606CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
MIRAMIRA Pharmaceuticals Inc
$ 3.55
(415.39%)
109.37M
CMAXCareMax Inc
$ 4.01
(153.80%)
46.22M
SERVServe Robotics Inc
$ 11.3307
(50.08%)
107.54M
SAVACassava Sciences Inc
$ 13.03
(29.27%)
7.63M
LPSNLivePerson Inc
$ 1.23
(24.24%)
3.08M
LGCBLinkage Global Inc
$ 3.67
(-29.63%)
117.88k
SLNASelina Hospitality PLC
$ 0.0353
(-25.37%)
45.08M
GSUNGolden Sun Health Technology Group Ltd
$ 5.03
(-25.15%)
97.13k
CGBSCrown LNG Holdings Ltd
$ 1.09
(-22.70%)
1.77M
MEDSTRxADE Health Inc
$ 11.6928
(-20.67%)
86.53k
NVDANVIDIA Corporation
$ 121.11
(2.70%)
123.95M
NCPLNetcapital Inc
$ 0.1081
(3.94%)
111.15M
MIRAMIRA Pharmaceuticals Inc
$ 3.55
(415.39%)
109.37M
SQQQProShares UltraPro Short QQQ
$ 8.29
(-2.01%)
108.21M
SERVServe Robotics Inc
$ 11.3307
(50.08%)
107.54M

MMED Discussion

View Posts
MomsSpaghetti MomsSpaghetti 5 days ago
This will go absolutely nuts. There is so much positivity surrounding this:

MDMA therapy gets support from prominent research group as FDA weighs action

https://www.greenmarketreport.com/mdma-therapy-gets-support-from-prominent-research-group-as-fda-weighs-action/

Once this is main stream it will be above 100.00 :)
👍️0
BefallenKnight BefallenKnight 5 days ago
Yup. FDA BTD, patent and Phase 3 Info. This is about to pop off. Pretty large OI in the Jan 2025 monthlies at 17.5 so I think we see 15 pretty soon.

At $5b annual revs (which I think is low) MNMD has the potential to become a triple digit stock in no time.

My guess is a buyout is imminent but there’s still that pesky Controlled Substances Act that acts as a wall for big pharma. When psychedelics are re-scheduled, this goes bonkers
👍️0
MomsSpaghetti MomsSpaghetti 5 days ago
Official press release from the patent issued yesterday

https://finance.yahoo.com/news/mindmed-announces-issuance-patent-mm120-110000178.html
👍️ 1
MomsSpaghetti MomsSpaghetti 6 days ago
Patent issued July 19 - LYOPHILIZED ORALLY DISINTEGRATING TABLET FORMULATIONS OF d-LYSERGIC ACID DIETHYLAMIDE FOR THERAPEUTIC U.S. PATENT DOCUMENT

https://ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12036220
👍️0
MomsSpaghetti MomsSpaghetti 6 days ago
Been here since day 1. As I am sure many here are. The first ride was hype. Just watch what this does when any commercialization gear starts turning. Going to be a rare show.
👍️0
Jack Torrance Jack Torrance 7 days ago
Phase 3 incoming and Breakthrough Therapy designation. People have no clue how rare those things are for a biotech startup in a BRAND NEW class of drugs in one of the BIGGEST pharmacology sectors (mental health). This company is a powder keg for the next year or so. When phase 3 results are good enough for FDA approval (which they most likely will be), the share price will explode and/or they will be bought out by one of the big boys. Accumulate the lows and hold.
👍️0
MomsSpaghetti MomsSpaghetti 7 days ago
Time to get in while attention is elsewhere. Going to rip again.
👍️0
LORTAP KCOTS LORTAP KCOTS 3 weeks ago
Yes but over $3
👍️0
Monksdream Monksdream 3 weeks ago
MNMD under $10
👍️0
MomsSpaghetti MomsSpaghetti 3 weeks ago
MindMed to be Included in Russell 2000® and Russell 3000® Indexes

https://www.businesswire.com/news/home/20240628586419/en/MindMed-to-be-Included-in-Russell-2000%C2%AE-and-Russell-3000%C2%AE-Indexes

June 28, 2024 07:00 AM Eastern Daylight Time

NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced today that as part of the annual reconstitution of the Russell stock indexes, the Company will be included in the Russell 2000® Index and the broad-market Russell 3000® Index, effective today.

“We are pleased to join the Russell Indexes and look forward to continuing to share our story with a broader audience of investors.”
Post this

“MindMed’s inclusion in the Russell Indexes mark an exciting milestone and reflects growing recognition of our commitment to addressing the unmet medical needs for people with brain health disorders by advancing MM120 for the treatment of general anxiety disorder and MM402 for the treatment of autism spectrum disorder,” said Rob Barrow, Chief Executive Officer of MindMed. “We are pleased to join the Russell Indexes and look forward to continuing to share our story with a broader audience of investors.”

Membership in the Russell 3000® Index means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000® Index as well as in the appropriate growth and value style indexes. The Russell 3000® Index encompasses the 3,000 largest U.S.-traded stocks by objective, market-capitalization rankings, and style attributes. Membership in these indexes is updated annually and remains in place for one year.

The Russell Indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $9.1 trillion in assets are benchmarked against Russell's U.S. Indexes. Russell Indexes are part of FTSE Russell, a leading global index provider.

For more information on the Russell Indexes and the Russell U.S. Indexes Reconstitution, visit the "Russell Reconstitution" section on the FTSE Russell website.

About MindMed

MindMed is a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative drug candidates, with and without acute perceptual effects, targeting the serotonin, dopamine, and acetylcholine systems.
👍️ 1
MomsSpaghetti MomsSpaghetti 1 month ago
MindMed Announces Constructive End-of-Phase 2 Meeting with U.S. FDA for MM120 in Generalized Anxiety Disorder (GAD)

-Aligned on requirements for Phase 3 clinical development of MM120 for the treatment of GAD-

-Initiation of Phase 3 program remains on schedule to begin in second half of 2024-

https://www.businesswire.com/news/home/20240620626324/en/

June 20, 2024 07:00 AM Eastern Daylight Time

NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the completion of the End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA), supporting the advancement of MM120 (lysergic acid diethylamide [LSD] D-tartrate) into pivotal trials for the treatment of adults with GAD.

“On behalf of the 20 million people in the U.S. – and millions more worldwide – who are living with GAD, we are incredibly excited for the therapeutic potential that MM120 shows based on the data from the previously completed Phase 2b MMED008 trial”
Post this

“Following a constructive End-of-Phase 2 meeting with the FDA, we are pleased to have reached alignment on our Phase 3 development strategy for MM120 in GAD,” said Rob Barrow, Chief Executive Officer of MindMed. “This marks a significant milestone for MindMed and for the millions of individuals affected by GAD. We are on schedule to initiate our Phase 3 clinical program for MM120 oral dissolving tablet (ODT) in GAD in the second half of this year and look forward to sharing additional details on the design of our pivotal program in the coming months.”

The EOP2 meeting was supported by results from MindMed’s completed Phase 2b clinical trial, MMED008. The multi-center, randomized, double-blind, parallel-group, dose-finding study was designed to assess the effect of four doses of MM120 for the treatment of anxiety symptoms in participants diagnosed with GAD. In the trial, MM120 met its primary and key secondary endpoints and demonstrated a rapid, clinically meaningful, and statistically significant improvements on the Hamilton Anxiety rating scale (HAM-A) at Week 4 and Week 12, with a 65% clinical response rate and 48% clinical remission rate sustained to Week 12 in the MM120 100 µg cohort. MM120 was generally well-tolerated in this trial, with most adverse events rated as mild to moderate, transient, and occurring on the dosing day and being consistent with the expected acute effects of the trial drug.

“On behalf of the 20 million people in the U.S. – and millions more worldwide – who are living with GAD, we are incredibly excited for the therapeutic potential that MM120 shows based on the data from the previously completed Phase 2b MMED008 trial,” said Daniel R. Karlin, MD, MA, Chief Medical Officer of MindMed. “Few treatment options have shown robust activity in GAD, with the last new FDA approval occurring in 2007. We are committed to bringing MM120 to people living with GAD and are excited to move into the next phase of our development program.”

About MM120

LSD (lysergide) is a synthetic ergotamine belonging to the group of classic, or serotonergic, psychedelics, which acts as a partial agonist at human serotonin-2A (5-hydroxytryptamine-2A [5-HT2A]) receptors. MindMed is developing MM120, the tartrate salt form of lysergide, for GAD and is exploring its potential applications in other serious brain health disorders.

About Generalized Anxiety Disorder (GAD)

GAD is a common condition associated with significant impairment that adversely affects millions of people. GAD results in fear, persistent anxiety, and a constant feeling of being overwhelmed. It is characterized by excessive, persistent, and unrealistic worry about everyday things. Approximately 10% of U.S. adults, representing around 20 million people, currently suffer from GAD. This underdiagnosed and underserved indication is associated with significant impairment, less accomplishment at work and reduced labor force participation. Despite the significant personal and societal burden of GAD, there has been little innovation in the treatment of GAD in the past several decades, with the last new drug approval occurring in 2007.

About MindMed

MindMed is a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health disorders. MindMed trades on NASDAQ under the symbol MNMD.
👍️ 1
Tiger Money Tiger Money 1 month ago
So right. FDA is disaster and they are supposed to be looking out for the human race. What a joke
👍️0
Giovanni Giovanni 1 month ago
Thank You
👍️ 1
BefallenKnight BefallenKnight 1 month ago
What a ridiculous article
A small handful of people have adverse effects from mushroom chocolates and the FDA issues a warning??? Meanwhile, as I’m typing this a dozen people died of fentanyl overdoses, 100 people just died from boozing and 3000 people croaked from cigs. Oh yeah, and scores of people also got seriously ill from contaminated meat, poultry and produce from CAFO or Monsanto mega farms.

Vomiting is not uncommon with higher doses of psilocybin, mescaline and even LSD. Vomiting is also extremely common with alcohol.

Abnormal heart rates are not only common with ALL drugs, one of the very means of classifying something as a drug is the substance’s effect on heart rates. Unlike cocaine or heroin I have never heard of a user experiencing cardiac arrest as the result of taking mushrooms or LSD.

Depression and/or seizures would be cause by underlying issues and not a direct result of drug use with the slightest possible exception of profound, extended use but even then underlying factors would be the main contributor.

The FDA is a joke with this bipolar nonsense. One minute they fast track MNMD’s LSD medicine, the next minute they warn about dangers of psychedelic meds…….pure comedy
👍️ 2
Semperfiguy Semperfiguy 1 month ago
To anyone with experience with psilocybin it is evident this report it totally blown out of context. Yes, temporary nausea is common for some at higher doses - no big deal and it can be managed. Seizures and depression are very uncommon and are likely a result of dosage abuse and state of mind of the user pre usage. Abnormal heart rates also uncommon at concerning levels for psilocybin, but are frequently a side effect from chocolate for those sensitive to caffeine. My wife can only eat a small amount of dark chocolate and never in the evening or she gets heat racing/anxiety feeling.
👍️0
Giovanni Giovanni 1 month ago
Sounds very similar to the poorly and or uninformed. That's me.
Please pardon my ignorance ,What is the difference?
TIA
👍️0
MomsSpaghetti MomsSpaghetti 1 month ago
Again, another reason why I'm invested in mind mode they are actually a medical company and not screwing around with things that they shouldn't be. Extremely bullish on them.
👍️0
Giovanni Giovanni 1 month ago
FOOD & DRINK
Microdosing chocolate bars leads to seizures, heart issues, vomiting and hospitalizations, FDA warns
By Social Links forAlex Mitchell
Published June 10, 2024, 7:22 p.m. ET

21 Comments
The Food and Drug Administration is warning that a chocolate bar laced with mushrooms is causing a bevy of serious health problems with users.

Diamond Shruumz-brand Microdosing Chocolate Bars are designed for consumers to engage with mushrooms in tiny increments.

However, multiple people nationwide who ate the chocolate — the brand’s website calls them “a subtle, sumptuous experience and a more creative state of mind” — experienced seizures, depression, vomiting and “abnormal heart rates.”

Others reportedly passed out after taking the $25 bars along with becoming confused or agitated, according to the FDA.

A brand of mushroom infused chocolate can be dangerous to eat, warns the FDA.
3
A brand of mushroom infused chocolate can be dangerous to eat, warns the FDA.
Getty Images/iStockphoto
A brand of mushroom candy bars is causing severe health issues.
3
A brand of mushroom candy bars is causing severe health issues.
FDA
EXPLORE MORE
Bella Hadid stuns in all Gucci hot pants, jacket, belt and platform shoes in New York City
‘Ugly’ millennial fashion accessory is making a comeback: ‘So happy I didn’t get rid of mine’
Dublin Airport baggage handler John revealed baggage attachments set back passenger's suitcase arrival.
Baggage handler issues warning to passengers who tie ribbons to their suitcases

Why Gen X is getting cancer more often than their parents' generation
So far, there have been eight cases reported: four in Arizona, two in Indiana, one in Nevada and another in Pennsylvania.

Of the confirmed cases, six people have been hospitalized.

“Consumers should not eat, sell, or serve any flavor of Diamond Shruumz-brand Microdosing Chocolate Bars, and should discard them,” the FDA warned consumers while also instructing retailers “not to sell or distribute” the product and to instead hold it “in a secure location until additional instructions can be provided on how to return or safely dispose of the product.”

The government agency also warned that the full list of retailers selling the brand “is currently unknown,” but it is specifically marketed as candy to young people.

The FDA warns to not buy the product.
👍️0
MomsSpaghetti MomsSpaghetti 1 month ago
excellent recovery today
👍️0
MomsSpaghetti MomsSpaghetti 1 month ago
Totally not concerned - I have quite the sizable holding in MNMD. Over the next few years we are going to see some interesting shifts happen. MindMed will be one of the ones on top. I have no doubts.
👍️0
LORTAP KCOTS LORTAP KCOTS 2 months ago
Bought 500 shares today
👍️0
BefallenKnight BefallenKnight 2 months ago
Bees don’t waste time
Telling flies
That honey tastes better
Than shit

MNMD is gonna be a millionaire maker regardless of the crooked by the FDA, DEA, pharma and other adversarial groups.
👍️0
Savannah-Marc Savannah-Marc 2 months ago
I think Kevin O'Leary may be right in that the smaller companies in the psychedelic space may merge to maximize the effect of their resources and these smaller companies may rally around MindMed! The news about Lykos is nothing! Remember Karuna....$$$$
👍️ 1 😎 1
MomsSpaghetti MomsSpaghetti 2 months ago
Oh this company will be one of the leaders. Lycos messed up. Rick Doblin is having a bad day. Rob Barrow is not. Shareholders here are fine.
👍️ 1 💯 1
Savannah-Marc Savannah-Marc 2 months ago
I hated to do what I did but I sold my MNMD shares for a considerable gain last month and invested in RONN. I am still very very bullish on MNMD and this recent pull back shouldn't alarm anybody as I believe the company is still vastly undervalued according to the research I've done. If all goes according to plan with RONN, I wish to buy back an even bigger position with MNMD as I still feel confident on MindMed's molecules being successful in FDA clinical trials. Best wishes and keep fighting for the company, I'm hoping to come back!!!
👍️ 1 😎 1
MomsSpaghetti MomsSpaghetti 2 months ago
This does not affect us. Good recovery so far. We will be fine. Bad trial design on Lycos part.
👍️ 1 🫡 1
Tiger Money Tiger Money 2 months ago
Great buying opportunity perhaps as they still have their mushroom drug that is in phase 3
👍️ 1 💯 1
bubka bubka 2 months ago
This selloff of psychedelic drugs across the board is due to the FDA rejection of private company Lykos Therapeutics’ MDMA drug for PTSD. This is certainly a knee jerk, overdone reaction in relation to MNMD.

https://www.npr.org/sections/shots-health-news/2024/06/04/nx-s1-4991112/mdma-therapy-ptsd-fda-advisors
👍️ 1 💯 1
LORTAP KCOTS LORTAP KCOTS 2 months ago
Should be buying now
👍️ 1 ♥️ 1
Tiger Money Tiger Money 2 months ago
Yes it was
👍️0
Monksdream Monksdream 2 months ago
Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc
👍️0
MomsSpaghetti MomsSpaghetti 2 months ago
Nice after hour spike!
👍️0
Tiger Money Tiger Money 2 months ago
This stock may need a little of its own medicine:)
👍️0
Tiger Money Tiger Money 2 months ago
This stock is resilient. Tells me the institutional longs have no desire to sell until we are significantly higher. $50-100 range. The market for their product is almost Infiniti
👍️0
Tiger Money Tiger Money 2 months ago
Agreed
👍️ 1 🫡 1
Savannah-Marc Savannah-Marc 2 months ago
MNMD recovering!
Bullish!!!!!!!!!!!!!!!!!!!!!
👍️ 1 💥 1
Savannah-Marc Savannah-Marc 2 months ago
Multi-billion dollar valuations are approaching.
https://www.businesswire.com/news/home/20240508064415/en/MindMed-Reports-First-Quarter-2024-Financial-Results-and-Business-Updates
👍️ 1 📈 1 🤡 1
burner67 burner67 2 months ago
Not a lie. Completely different drugs. Do you have Google Marc?
💩 1 🤡 1
Savannah-Marc Savannah-Marc 3 months ago
And I quote:

Savannah-Marc
04/14/24 2:40 PM
Post #9,370
Keep your eye on the prize my fellow MindMed shareholders. A company with a similar profile was bought out for $14 billion while still in FDA Phase 3 clinical trials and WITHOUT FDA Breakthrough designation! Know what you own! Stay well my people!
https://www.biopharmadive.com/news/bristol-myers-karuna-acquire-schizophrenia-kar-xt/703313/
🌋 1 👍️ 1
Savannah-Marc Savannah-Marc 3 months ago
You say things and spin lies like they matter. Your opinions are worthless on whatever board you try and yuck it up on. Stick to giving "stock tips" from the drive thru window and don't forget the ketchup packets, that's the most important part!
🍟 1 👍️ 1
burner67 burner67 3 months ago
How are they similar? Because they're both in phase 3? You could say that about hundreds of drugs. KarXT is NOT a psychedelic while MindMed's drugs are all pcychedelics, so not similar.
💩 1 🤡 1
burner67 burner67 3 months ago
Typical response 🤣
👍️0
Savannah-Marc Savannah-Marc 3 months ago
AWESOME!!!!!
👍️ 1 😎 1
MomsSpaghetti MomsSpaghetti 3 months ago
MindMed Presents Phase 2b Study of MM120 for Generalized Anxiety Disorder (GAD) at American Psychiatric Association (APA) Annual Meeting in New York

https://finance.yahoo.com/news/mindmed-presents-phase-2b-study-120000301.html
👍️ 1 🥇 1
MomsSpaghetti MomsSpaghetti 3 months ago
I have never seen a PR on a Saturday.
👍️ 1 🤩 1
Monksdream Monksdream 3 months ago
MNMD 10 day hourly
👍️ 1 📈 1
Tiger Money Tiger Money 3 months ago
I think so
👍️ 1 💯 1
Monksdream Monksdream 3 months ago
Maybe back to $12 next week
👍️ 1 📈 1
Savannah-Marc Savannah-Marc 3 months ago
MindMed will be the vanguard of the shroom boom, only a matter of time before this trades in the BILLIONS!!!!!
👍️ 1 🤡 1 🥇 1
Tiger Money Tiger Money 3 months ago
Agreed
👍️ 1 🫡 1

Your Recent History

Delayed Upgrade Clock